If you're taking a GLP-1 medication like Ozempic, Wegovy, or Mounjaro, you may have heard whispers about thyroid risks. Let's cut through the noise and look at what the science actually says.
Wondering about GLP-1 and thyroid function? Learn the real risks, who should be cautious, and what monitoring you need while on these medications.
What Is GLP-1 and How Does It Work?
GLP-1 (glucagon-like peptide-1) is a hormone your gut releases after eating. It tells your pancreas to release insulin, slows down digestion, and sends fullness signals to your brain. GLP-1 medications mimic this hormone, helping people with type 2 diabetes and obesity manage blood sugar and lose weight.
These medications include semaglutide (Ozempic, Wegovy), tirzepatide (Mounjaro, Zepbound), liraglutide (Saxenda, Victoza), and dulaglutide (Trulicity).
Track your labs and see how your protocol moves your biomarkers.
Track it in the appThe Thyroid Connection: What Research Shows
Here's where things get interesting. GLP-1 receptors are found in the thyroid gland, particularly in cells called C-cells that produce calcitonin. In rodent studies, long-term exposure to GLP-1 medications caused thyroid tumors. However, the relevance to humans has not been conclusively established.
What we know from human data:
- Cases of thyroid cancer have been reported in patients using GLP-1 medications, but the absolute risk appears very low
- The FDA added a boxed warning to certain GLP-1 medications about potential thyroid C-cell tumors
- Most cases occurred in patients with a personal or family history of medullary thyroid carcinoma (MTC) or Multiple Endocrine Neoplasia type 2 (MEN2)
